Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers
Publication Date: July 14, 2020
Key Points
Key Points
- Chemotherapy-induced neuropathy (CIPN) is a serious clinical problem caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib.
- No agents are recommended for the prevention of CIPN.
- Duloxetine is the only agent that has appropriate evidence to support its use, but the amount of benefit from duloxetine is limited.
- Therefore, prevention and minimizing risk are the primary objectives.
- Because patients with CIPN can have balance troubles and a higher chance of falling, it is reasonable to consider physical and/or occupational therapy approaches for patients with such CIPN-related disabilities.
Prevention
...vention
...chemotherapy-induced peripheral neuropathy...
...endation 1.1Clinicians should assess the risks a...
...dation 1.2Clinicians should NOT offer, an...
...1.3Outside the context of a clinical trial, no re...
...dation 1.4Clinicians should NOT offer the follow...
Treatment
...reatmen...
...hemotherapy-induced peripheral neur...
...2.1Clinicians should assess, and disc...
...ent of chemotherapy-induced peripheral neuropathy...
...ion 3.1For cancer patients experiencing painful C...
Recommendation 3.2Outside the context of a clinica...
Summary of Recommendations
Summary of RecommendationsHaving trouble vi...